Amy is a managing partner at Polaris Partners who focuses on investing in healthcare companies and early stage biotech start-ups.
She serves as chair of the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY). She also represents Polaris as a director of ByHeart, Kallyope, Thirty Madison, QurAlis, and Larkspur. Amy serves on the Boards of Action Against Hunger, Mount Sinai Hospital (where she co-chairs the Innovations Committee), and the California Institute of Technology. She is a member of Singapore’s Health and Biomedical Sciences International Advisory Council and the LifeSci NYC Advisory Council.
Amy joined Polaris in 2014, and in 2017 she co-founded the Polaris Innovation Fund, which she continues to manage today, in addition to her role as a managing partner of the Polaris main funds.
Before Polaris, Amy worked at Pfizer, where she held several roles, beginning with general counsel and moving to the business side as president of both Pfizer Nutrition and Pfizer Consumer Healthcare. She practiced law as a partner at DLA Piper and began her career in litigation with Cleary Gottlieb Steen & Hamilton in 1991.
Amy has received numerous awards, including the Margaret Brent Women Lawyers of Achievement Award, Scientific American’s Worldview 100 List, Fierce Biotech’s Top 15 Women in Biotech, and Fortune Magazine’s 50 Most Powerful Women in Business.
Amy is a Phi Beta Kappa graduate of Wesleyan University with a joint degree in philosophy and english and earned her J.D. from Yale Law School.